GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Akili Inc (NAS:AKLI) » Definitions » Cash Ratio
中文

Akili (AKLI) Cash Ratio

: 5.80 (As of Dec. 2023)
View and export this data going back to 2022. Start your Free Trial

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Akili's Cash Ratio for the quarter that ended in Dec. 2023 was 5.80.

Akili has a Cash Ratio of 5.80. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Akili's Cash Ratio or its related term are showing as below:

AKLI' s Cash Ratio Range Over the Past 10 Years
Min: 4.72   Med: 6.14   Max: 10.01
Current: 5.8

During the past 5 years, Akili's highest Cash Ratio was 10.01. The lowest was 4.72. And the median was 6.14.

AKLI's Cash Ratio is ranked better than
94% of 650 companies
in the Healthcare Providers & Services industry
Industry Median: 0.51 vs AKLI: 5.80

Akili Cash Ratio Historical Data

The historical data trend for Akili's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akili Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
6.14 4.72 9.56 10.01 5.80

Akili Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.01 10.28 8.05 6.61 5.80

Competitive Comparison

For the Health Information Services subindustry, Akili's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akili Cash Ratio Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Akili's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Akili's Cash Ratio falls into.



Akili Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Akili's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=75.15/12.967
=5.80

Akili's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=75.15/12.967
=5.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akili  (NAS:AKLI) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Akili Cash Ratio Related Terms

Thank you for viewing the detailed overview of Akili's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akili (AKLI) Business Description

Traded in Other Exchanges
Address
125 Broad Street, Fifth Floor, Boston, MA, USA, 02110
Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.
Executives
Jacqueline Studer officer: Chief Legal Officer IDEXX LABORATORIES, ONE IDEXX DRIVE, WESTBROOK ME 04092
Matthew Franklin officer: See Remarks AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Martucci Walter Edward Ii director, officer: Chief Executive Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Santosh Shanbhag officer: Chief Financial Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Chamath Palihapitiya director, 10 percent owner THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Mary Hentges director C/O SHOTSPOTTER, INC., 7979 GATEWAY BLVD., STE. 210, NEWARK CA 94560
Tls Beta Pte. Ltd. 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Temasek Holdings (private) Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Fullerton Management Pte Ltd 10 percent owner 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Anil Jina officer: Chief Medical Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Temasek Life Sciences Private Ltd 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Jonathan David officer: Chief Product Officer AKILI INTERACTIVE LABS, INC., 125 BROAD STREET 5TH FLOOR, BOSTON MA 02110
Kenneth Ehlert director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Christine Lemke director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110
Adam Gazzaley director AKILI INTERACTIVE LABS, INC., 125 BROAD STREET, 5TH FLOOR, BOSTON MA 02110